Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

P&G Says Zegerid Switch Proposal Should Drop “Immediate Release” Claim

This article was originally published in The Tan Sheet

Executive Summary

The proton pump inhibitor Zegerid should not be allowed on the over-the-counter market with the label claim "immediate release," says Prilosec OTC marketer Procter & Gamble
Advertisement

Related Content

P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits
P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits
P&G Targets Proposed Nexium Switch In Petition For PPI Labeling Limits
Zegerid OTC Approved, Limited To Touting Dual-Ingredient Formula For Now
FDA Denies P&G Petition For OTC Proton Pump Inhibitor Class Labeling
P&G Asks FDA To Make Prilosec The Standard For OTC PPI Claims
Schering-Plough’s Zegerid Switch Stumbles As FDA Questions Application
Sea Changes In Regulation And The Market: Top Stories Of 2008
Zegerid on track
P&G Braces For “Tough Year” Of Navigating Turbulent Economy

Topics

Advertisement
UsernamePublicRestriction

Register

PS102388

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel